BioClinica, Inc.,
a global provider of clinical trial management services, will exhibit at the 46th Drug Information Association (DIA) Annual Meeting from June 13- 17, 2010 in Washington, D.C., where it will showcase the BioClinica eClinical Technology Suite as well as introduce the BioClinica Integrated Operations Platform (BIOP). This advancement in clinical support technology uses Microsoft Office and SharePoint platforms to deliver a real world window on clinical operations.
This development will enable BioClinica to make operational data accessible in Microsoft Office and SharePoint applications that most customers already use.
“Our customers told us that they needed a simpler way to centralize and share their operational data for managing clinical trials. Through our work with Microsoft we are embracing the SharePoint and Office tools that many customers already have and use. Unlike other solutions, this platform untethers the clinical data, making the data more easily accessible and therefore more usable,"said Mark Weinstein, CEO of BioClinica.
The SharePoint platform delivers increased workflow efficiencies among life sciences colleagues, partners and customers. BioClinica CTMS utilizes SharePoint, creating customer oversight to eClinical workflow and access to data and reports through the Microsoft Office platform.
“To keep up with market demands, life sciences companies are under increased pressure to speed the pace of clinical trials and quickly bring new drugs to market,” said Michael Naimoli, director of life sciences industry solutions, Microsoft. “With the integration of our Office and SharePoint platforms, BioClinica customers can liberate their data for a comprehensive, real-time view into studies and pertinent information, with Office Smart clinical trial management systems.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.